Explore the Global Cytokine Release Syndrome Management Market — Key Trends, Regional Growth, Top Players, and 10-Year Forecast from 2026 to 2036

Future Market Insights

Cytokine Release Syndrome Management Market

Key Insight

Cytokine release syndrome management sales will expand through 2036, with interleukins (IL-2) holding 42.6% of the cytokine type segment in 2026. The market was valued at USD 26.55 billion in 2025 and is expected to be worth USD 51.45 billion by 2036, creating an incremental opportunity of USD 23.26 billion.

April 28, 2026

Anurag Sharma

290 Pages

Cite this Report

Cytokine Release Syndrome Management Market

https://www.futuremarketinsights.com/reports/cytokine-release-syndrome-management-market

License

Starting at US$ 5000

Buy Now

Summary ToC Infographics Companies

Key Players

Arcellx
BlackRock
Bristol-Myers Squibb
Eli Lilly and Company
Genentech (Roche Holding AG)
Kite Pharma
Legend Biotech
Novartis
The Vanguard Group
Regeneron Pharmaceuticals
L'Oréal

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Cytokine Release Syndrome Management Market

Key Players

Similar Industry Reports